Completed PHASE3 INTERVENTIONAL 3-arm NCT01689246

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Sponsor: TauRx Therapeutics Ltd

Conditions Alzheimer's Disease

Interventions Placebo TRx0237 150 mg/day TRx0237 250 mg/day

Updated 8 times since 2017 Last updated: Mar 12, 2018 Started: Jan 31, 2013 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Alzheimer's Disease and is currently completed. TauRx Therapeutics Ltd leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TauRx Therapeutics Ltd

Data source: TauRx Therapeutics Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Achim, Germany , Adelaide, Australia , Albany, United States , Arad, Romania , Atlantis, United States , Austin, United States , Bath, United Kingdom , Belfast, United Kingdom , Berlin, Germany and 84 more locations